Abstract
Background
Malignant bowel obstruction (MBO) is a frequent complication in patients with advanced cancer, particularly colon or gynecological malignancies. MASCC previously published a guideline for symptom management of MBO in 2017. This is a 5-year update.
Method
A systematic search and review of relevant literature includes a review published in 2010 and 2017. The guideline update used the same literature search process as followed in 2015. The dates of the new search included 2015 up to February 2, 2021. The guidelines involved the pharmacologic management of nausea and vomiting in malignant bowel obstruction (MBO) only. Only randomized trials were included in the updated guideline as evidence. The evidence was reviewed by the panel and the MASCC criteria for establishing a guideline were followed using MASCC level of grading and category of evidence.
Results
There was one systematic review and 3 randomized trials accepted as evidence from 257 abstracts. Octreotide is effective in reducing gastrointestinal secretions and colic and thereby reduces nausea and vomiting caused by MBO. Scopolamine butylbromide is inferior to octreotide in the doses used in the comparison study. Olanzapine or metoclopramide may be effective in reducing nausea and vomiting secondary to partial bowel obstructions. The panel suggests using either drug. Additional studies are needed to clarify benefits. Haloperidol has been used by convention as an antiemetic but has not been subjected to a randomized comparison. Ranitidine plus dexamethasone may be effective in reducing nausea and vomiting from MBO but cannot be recommended until there is a comparison with octreotide.
Discussion
Octreotide remains the drug of choice in managing MBO. Ranitidine was used in one randomized trial in all participants and so its effectiveness as a single drug is not known until there is a randomized comparison with octreotide. Antiemetics such as metoclopramide and olanzapine may be effective, but we have very few randomized trials of antiemetics in MBO.
Conclusion
The panel recommends octreotide in non-operable MBO. Randomized trials are needed to clarify ranitidine and antiemetic choices.
Similar content being viewed by others
Data Availability
NA
Code availability
NA
References
Huang X, Xue J, Gao M et al (2020) Medical management of inoperable malignant bowel obstruction. Ann Pharmacother. 55(9):1134–1145. https://doi.org/10.1177/1060028020979773
Ripamonti CI, Easson AM, Gerdes H (2008) Management of malignant bowel obstruction. Eur J Cancer. 44(8):1105–1115
Ripamonti C, Bruera E (2002) Palliative management of malignant bowel obstruction. Int J Gynecol Cancer. 12(2):135–143
Soriano A, Davis MP (2011) Malignant bowel obstruction: individualized treatment near the end of life. Cleve Clin J Med. 78(3):197–206
Ang SK, Shoemaker LK, Davis MP (2010) Nausea and vomiting in advanced cancer. Am J Hosp Palliat Care. 27(3):219–225
Fainsinger RL, Spachynski K, Hanson J, Bruera E (1994) Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage. 9(1):12–18
Bleicher J, Lambert LA (2021) A palliative approach to management of peritoneal carcinomatosis and malignant ascites. Surg Oncol Clin N Am. 30(3):475–490
Davis MP, Hallerberg G (2010) Palliative Medicine Study Group of the Multinational Association of Supportive Care in C. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manage. 39(4):756–767
Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A (2017) 2016 Updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer. 25(1):333–340
Ripamonti C, De Conno F, Ventafridda V, Rossi B, Baines MJ (1993) Management of bowel obstruction in advanced and terminal cancer patients. Ann Oncol. 4(1):15–21
Ripamonti C, Panzeri C, Groff L, Galeazzi G, Boffi R (2001) The role of somatostatin and octreotide in bowel obstruction: pre-clinical and clinical results. Tumori. 87(1):1–9
Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L (2000) Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer. 8(3):188–191
Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A (2000) Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage. 19(1):23–34
Mercadante S, Casuccio A, Mangione S (2007) Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage. 33(2):217–223
Mercadante S (1998) Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction. J Pain Symptom Manage. 16(5):278–280
Mercadante S (1995) Bowel obstruction in home-care cancer patients: 4 years experience. Support Care Cancer. 3(3):190–193
Mercadante S, Spoldi E, Caraceni A, Maddaloni S, Simonetti MT (1993) Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med. 7(4):295–299
Shima Y, Ohtsu A, Shirao K, Sasaki Y (2008) Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol. 38(5):354–359
Shima Y, Yamaguchi K, Miyata Y, Hyodo I, Yagi Y, Honke Y (2004) A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient. Gan To Kagaku Ryoho. 31(9):1377–1382
Khoo D, Riley J, Waxman J (1992) Control of emesis in bowel obstruction in terminally ill patients. Lancet. 339(8789):375–376
Philip J, Lickiss N, Grant PT, Hacker NF (1999) Corticosteroids in the management of bowel obstruction on a gynecological oncology unit. Gynecol Oncol. 74(1):68–73
Mangili G, Franchi M, Mariani A, Zanaboni F, Rabaiotti E, Frigerio L, Bolis PF, Ferrari A (1996) Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol. 61(3):345–348
Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, de Conno F, Gemlo B, Hunt TM, Krebs HB, Mercadante S, Schaerer R, Wilkinson P, Working Group of the European Association for Palliative Care (2001) Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 9(4):223–233
De Conno F, Caraceni A, Zecca E, Spoldi E, Ventafridda V (1991) Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage. 6(8):484–486
Obita GP, Boland EG, Currow DC, Johnson MJ, Boland JW (2016) Somatostatin analogues compared with placebo and other pharmacologic agents in the management of symptoms of inoperable malignant bowel obstruction: a systematic review. J Pain Symptom Manage. 52(6):901–919 e901
Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, Eckermann S, Abernethy AP, Clark K (2015) Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manage. 49(5):814–821
Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, Botton E, Beatrix O, Mayeur D, Herve R, Maisonobe P, Chauvenet L (2012) Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 30(35):4337–4343
McCaffrey N, Asser T, Fazekas B, Muircroft W, Agar M, Clark K, Eckermann S, Lee J, Joshi R, Allcroft P, Sheehan C, Currow DC (2020) Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide. BMC Cancer. 20(1):1050
Clark K, Lam L, Currow D (2009) Reducing gastric secretions--a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction? Support Care Cancer. 17(12):1463–1468
Itoh H (2006) Clinicopharmacological study of gastrointestinal drugs from the viewpoint of postmarketing development. Yakugaku Zasshi. 126(9):767–778
Peng X, Wang P, Li S, Zhang G, Hu S (2015) Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol. 13:50
Kaneishi K, Imai K, Nishimura K, Sakurai N, Kohara H, Ishiki H, Kanai Y, Oyamada S, Yamaguchi T, Morita T, Iwase S (2020) Olanzapine versus metoclopramide for treatment of nausea and vomiting in advanced cancer patients with incomplete malignant bowel obstruction. J Palliat Med. 23(7):880–881
Owyang C (1994) Octreotide in gastrointestinal motility disorders. Gut. 35(3 Suppl):S11–S14
Stolk MF, van Erpecum KJ, Koppeschaar HP, Samsom M, Smout AJ, Akkermans LM, Peeters TL, vanBerge-Henegouwen GP (1995) Effect of octreotide on fasting gall bladder emptying, antroduodenal motility, and motilin release in acromegaly. Gut. 36(5):755–760
Poitras P, Trudel L, Miller P, Gu CM (1997) Regulation of motilin release: studies with ex vivo perfused canine jejunum. Am J Physiol. 272(1 Pt 1):G4–G9
Ambartsumyan L, Flores A, Nurko S, Rodriguez L (2016) Utility of octreotide in advancing enteral feeds in children with chronic intestinal pseudo-obstruction. Paediatr Drugs. 18(5):387–392
Peeters TL, Romanski KW, Janssens J, Vantrappen G (1988) Effect of the long-acting somatostatin analogue SMS 201-995 on small-intestinal interdigestive motility in the dog. Scand J Gastroenterol. 23(7):769–774
Haruma K, Wiste JA, Camilleri M (1994) Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders. Gut. 35(8):1064–1069
van Berge Henegouwen MI, van Gulik TM, Akkermans LM, Jansen JB, Gouma DJ (1997) The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers. Gut. 41(6):758–762
Edmunds MC, Chen JD, Soykan I, Lin Z, McCallum RW (1998) Effect of octreotide on gastric and small bowel motility in patients with gastroparesis. Aliment Pharmacol Ther. 12(2):167–174
Richards WO, Geer R, O’Dorisio TM et al (1990) Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome. J Surg Res. 49(6):483–487
Cullen JJ, Eagon JC, Kelly KA (1994) Gastrointestinal peptide hormones during postoperative ileus. Effect of octreotide. Dig Dis Sci. 39(6):1179–1184
Nordesjo-Haglund G, Lonnqvist B, Lindberg G, Hellstrom-Lindberg E (1999) Octreotide for nausea and vomiting after chemotherapy and stem-cell transplantation. Lancet. 353(9155):846
Soudah HC, Hasler WL, Owyang C (1991) Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 325(21):1461–1467
Lecomte T, Cavicchi M, Delchier JC (2000) Small bowel pseudo-obstruction revealing an early scleroderma. Long-term efficacy of octreotide and erythromycin. Gastroenterol Clin Biol. 24(3):361–363
Dahaba AA, Mueller G, Mattiassich G, Rumpold-Seitlinger G, Bornemann H, Rehak PH, Linck G, Mischinger HJ, Metzler H (2009) Effect of somatostatin analogue octreotide on pain relief after major abdominal surgery. Eur J Pain. 13(8):861–864
Cullen JJ, Eagon JC, Dozois EJ, Kelly KA (1993) Treatment of acute postoperative ileus with octreotide. Am J Surg. 165(1):113–119 discussion 119-120
Wu Z, Wang S, Yuan S, Lin M (2020) Clinical efficacy and safety of somatostatin in the treatment of early postoperative inflammatory small bowel obstruction: a protocol for systematic review and meta analysis. Medicine (Baltimore). 99(20):e20288
Guignard JP, Herxheimer A, Greenwood RM (1968) Effects of hyoscine butylbromide on gut motility. Clin Pharmacol Ther. 9(6):745–748
Herxheimer A, de Groot AC (1977) Some effects of injected hyoscine butylbromide: a versatile class experiment in human pharmacology. Br J Clin Pharmacol. 4(3):337–342
Herxheimer A (1958) A comparison of some atropine-like drugs in man, with particular reference to their end-organ specificity. Br J Pharmacol Chemother. 13(2):184–192
Deakin M, Williams JG (1992) Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers. Drugs. 44(5):709–719
Konturek SJ, Radecki T, Brzozowski T, Piastucki I, Dembinska-Kiec A, Zmuda A (1981) Gastric cytoprotection by prostaglandins, ranitidine, and probanthine in rats. Role of endogenous prostaglandins. Scand J Gastroenterol. 16(1):7–12
Katsoulis S, Conlon JM (1989) Calcitonin gene-related peptides relax guinea pig and rat gastric smooth muscle. Eur J Pharmacol. 162(1):129–134
Tache Y, Pappas T, Lauffenburger M, Goto Y, Walsh JH, Debas H (1984) Calcitonin gene-related peptide: potent peripheral inhibitor of gastric acid secretion in rats and dogs. Gastroenterology. 87(2):344–349
Bauerfeind P, Hof R, Hof A, Cucala M, Siegrist S, von Ritter C, Fischer JA, Blum AL (1989) Effects of hCGRP I and II on gastric blood flow and acid secretion in anesthetized rabbits. Am J Physiol. 256(1 Pt 1):G145–G149
Itoh H, Naito T, Takeyama M (2002) Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide. J Pharm Pharmacol. 54(11):1559–1563
Bertaccini G, Scarpignato C (1982) Histamine H2-antagonists modify gastric emptying in the rat. Br J Pharmacol. 77(3):443–448
Ueki S, Seiki M, Yoneta T, Aita H, Chaki K, Hori Y, Morita H, Tagashira E, Itoh Z (1993) Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther. 264(1):152–157
Geppetti P, Del Bianco E, Patacchini R, Santicioli P, Maggi CA, Tramontana M (1991) Low pH-induced release of calcitonin gene-related peptide from capsaicin-sensitive sensory nerves: mechanism of action and biological response. Neuroscience. 41(1):295–301
Manela FD, Ren J, Gao J, McGuigan JE, Harty RF (1995) Calcitonin gene-related peptide modulates acid-mediated regulation of somatostatin and gastrin release from rat antrum. Gastroenterology. 109(3):701–706
Shimatani T, Inoue M, Kuroiwa T, Xu J, Nakamura M, Tazuma S, Ikawa K, Morikawa N (2006) Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine. Dig Dis Sci. 51(1):114–120
Yang HX, Luo D, Zou YY (2007) Effect of ranitidine on the gastric acid, plasma endothelin, and calcitonin gene-related peptide in patients undergoing the brain operation. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 32(2):295–298
Ren J, Young RL, Lassiter DC, Rings MC, Harty RF (1992) Calcitonin gene-related peptide: mechanisms of modulation of antral endocrine cells and cholinergic neurons. Am J Physiol. 262(4 Pt 1):G732–G739
Ren J, Dunn ST, Tang Y, Wang Y, Gao J, Brewer K, Harty RF (1998) Effects of calcitonin gene-related peptide on somatostatin and gastrin gene expression in rat antrum. Regul Pept. 73(2):75–82
Sandvik AK, Dimaline R, Forster ER, Evans D, Dockray GJ (1993) Differential control of somatostatin messenger RNA in rat gastric corpus and antrum. Role of acid, food, and capsaicin-sensitive afferent neurons. J Clin Invest. 91(1):244–250
Feuer DJ, Broadley KE (2000) Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2:CD001219
Feuer DJ, Broadley KE (1999) Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Systematic Review Steering Committee. Ann Oncol. 10(9):1035–1041
Author information
Authors and Affiliations
Contributions
Systematic search: Mellar Davis, David Hui; manuscript development and writing: Mellar Davis, Andrew Davies; editing and critiquing: David Hui, Andrew Davies, Carla Ida Ripamonti, Andreia Capela, Giulia DeFeo, Egidio Del Fabbro, Eduardo Bruera.
Corresponding author
Ethics declarations
Ethics approval
NA
Consent to participate
NA
Consent for publication
NA
Conflict of interest
David Hui grant from Helsinn.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
ESM 1
(DOCX 79 kb)
Rights and permissions
About this article
Cite this article
Davis, M., Hui, D., Davies, A. et al. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update. Support Care Cancer 29, 8089–8096 (2021). https://doi.org/10.1007/s00520-021-06438-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-021-06438-9